
Opinion|Videos|April 14, 2025
Adherence in Psoriasis Care: Barriers, Solutions, and the Road Ahead
A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and adherence among psoriasis patients treated with different biologics including tildrakizumab, risankizumab, guselkumab, and ustekinumab, with implications for clinical decision-making based on early versus late disease onset and prior biologic exposure.
Advertisement
Episodes in this series

- What challenges do you anticipate in maintaining high treatment adherence rates for psoriasis therapies?
- With increasing availability of targeted biologic therapies, how do you anticipate treatment strategies for psoriasis will continue to evolve?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Blinatumomab Boosts Survival in Pediatric ALL, but Faces Delivery Hurdles
2
Advancing Early Detection and Equitable Access in Alzheimer Disease Care
3
Digital Innovation and New Drugs Converge to Transform CRM Care
4
Bills to Address Expiring ACA Subsidies Fail to Pass Senate
5










































